Aktis Oncology, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Aktis Oncology, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-4.9×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 56% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 0/3Sales grew in 2 of the last 3 years; profit grew in 0 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-48.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 73% of Healthcare companies in United States.
Cash Cushion Ratio
+23%Cash, after subtracting all debt, equals 23% of its market value (net cash).
Higher than 65% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Aktis Oncology, Inc. made a loss over the last year. Aktis Oncology, Inc. owes $0.13 for every $1 it owns. Aktis Oncology, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAktis Oncology, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.92The share price is 1.92 times Aktis Oncology, Inc.'s book value per share, lower than 61% of Healthcare companies in United States.
Market cap
$932 MThe total market value of all of Aktis Oncology, Inc.'s shares at today's price (share price × number of shares), larger than 63% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$485 MWhat Aktis Oncology, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$8.72Net worth divided by the number of shares. The share price of $16.76 is 1.9 times this, which is the P/B above.
Owes vs Owns
0.13×Aktis Oncology, Inc. owes $0.13 for every $1 it owns (low), lower than 82% of Healthcare companies in United States.
Dividend yield
NoneAktis Oncology, Inc. does not currently pay a dividend.
Revenue growth
+337%Revenue rose 337% in the year to Dec 2025.
Profit growth
LossAktis Oncology, Inc. made a loss in each of the last two years.
Profit margin
-980.9%Aktis Oncology, Inc. lost $981 for every $100 of revenue.
Cash vs debt
Net cashAktis Oncology, Inc. held $215 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Aktis Oncology, Inc.: $932 M ÷ $485 M (30 Jun 2026) = 1.9.
How much does Aktis Oncology, Inc. owe compared with what it owns?
Aktis Oncology, Inc. owes $0.13 for every $1 it owns (low), lower than 82% of Healthcare companies in United States.
Does Aktis Oncology, Inc. pay a dividend?
No. Aktis Oncology, Inc. does not currently pay a dividend.
Is Aktis Oncology, Inc.'s revenue growing?
Revenue rose 337% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.